No Record Found
Sector
PharmaceuticalsOpen
₹82.8Prev. Close
₹82.8Turnover(Lac.)
₹3.25Day's High
₹83.87Day's Low
₹81.2152 Week's High
₹140.9552 Week's Low
₹78.06Book Value
₹62.28Face Value
₹10Mkt Cap (₹ Cr.)
131.27P/E
16.91EPS
4.91Divi. Yield
1.45No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | 
|---|---|---|---|---|
| Equity Capital | 15.92 | 15.8 | 15.69 | 15.76 | 
| Preference Capital | 0 | 0 | 0 | 0 | 
| Reserves | 82.9 | 77.03 | 80.34 | 71.56 | 
| Net Worth | 98.82 | 92.83 | 96.03 | 87.32 | 
| Minority Interest | 
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 | 
|---|---|---|---|---|
| Revenue | 249.3 | 170.67 | 223.07 | 209.84 | 
| yoy growth (%) | 46.07 | -23.49 | 6.3 | -7.13 | 
| Raw materials | -150.58 | -84.21 | -116.93 | -100.62 | 
| As % of sales | 60.39 | 49.34 | 52.41 | 47.94 | 
| Employee costs | -39.61 | -48.76 | -48.45 | -49.61 | 
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 | 
|---|---|---|---|---|
| Profit before tax | 9.79 | -9.07 | 4.41 | 8.45 | 
| Depreciation | -7.25 | -7.02 | -6.11 | -6.72 | 
| Tax paid | -0.69 | 0.17 | 2.34 | -2.51 | 
| Working capital | 21.59 | -16.12 | 17.18 | 19.67 | 
| Other operating items | 
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 | 
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | 46.07 | -23.49 | 6.3 | -7.13 | 
| Op profit growth | 289.87 | -66.75 | -10.21 | 12.42 | 
| EBIT growth | 551.42 | -80.28 | -3.55 | 2.99 | 
| Net profit growth | -202.18 | -231.68 | 13.83 | 11.75 | 
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | 
|---|---|---|---|---|---|
| Gross Sales | 303.08 | 339.22 | 304.22 | 281.21 | 250.53 | 
| Excise Duty | 0 | 0 | 0 | 0 | 0 | 
| Net Sales | 303.08 | 339.22 | 304.22 | 281.21 | 250.53 | 
| Other Operating Income | 0 | 0 | 0 | 0 | 0 | 
| Other Income | 2.2 | 2.85 | 0.98 | 5.15 | 1.14 | 
| Company Name | LTP (₹) | P/E  (%) | Mkt.Cap  (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield  (%) | Sales Qtr  (₹.Cr) | Book Value (₹) | 
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,703.4 | 82.06 | 4,08,750.71 | 753.53 | 0.94 | 5,566.68 | 101.44 | 
| Divis Laboratories Ltd DIVISLAB | 6,655 | 75.61 | 1,76,633.5 | 557 | 0.45 | 2,357 | 561.08 | 
| Cipla Ltd CIPLA | 1,540.1 | 23.94 | 1,24,437.16 | 1,210.53 | 1.04 | 4,495.16 | 411.56 | 
| Torrent Pharmaceuticals Ltd TORNTPHARM | 3,602.4 | 61.3 | 1,21,865.35 | 551 | 0.17 | 2,567 | 224.34 | 
| Mankind Pharma Ltd MANKIND | 2,446.6 | 55.79 | 1,00,950.41 | 412.76 | 0 | 2,541.36 | 354.69 | 
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Shailesh Siroya
Executive Director
Himesh Virupakshaya
Independent Director
Nicola Neeladri
Independent Director
Jatish Sheth
Whole-time Director
Kotian Chittananda Damodar
Company Sec. & Compli. Officer
Abdul Basith
21 & 22 Bommasandra Indl Area,
Hosur Road,
Karnataka - 560092
Tel: -
Website: http://www.balpharma.com
Email: investor@balpharma.com
C-101 1st Floor,
247 Park Vikhroli W, Lal Bahadur Marg,
Mumbai - 400 083
Tel: -
Website: www.tsrdarashaw.com
Email: csg-unit@tsrdarashaw.com
Summary
Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 87. In Mar.90, BPL took over a pharmaceutical products manufacturing unit located in...
Read More
Reports by Bal Pharma Ltd








 IIFL Customer Care Number
 IIFL Customer Care Number 
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000  / 7039-050-000
 IIFL Capital Services Support WhatsApp Number
 IIFL Capital Services Support WhatsApp Number
+91 9892691696


IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.